Preoperative CA 15.3 and prognosis in primary breast cancer

Clinical and Translational Oncology

Volumn 2, Issue 6, 2000, Pages 316-319

  Tornamira, M Victoria ^a   Montero, Sagrario ^a   Vargas, Carmela ^a   Guzmán, Cecilia ^a   Cortés Funes, Hernán ^a   Colomer, Ramón ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Breast carcinoma; CA 15.3; Disease free survival; MUC 1; Mucin; Prognosis

Indexed keywords

EID: 33750705427     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Overmoyer BA. Chemotherapeutic palliative approaches in the treatment of breast cancer. Semin Oncol 1995; 22: 2-9.
2. Price MR. Molecular weight epithelial mucins as markers in breast cancer. Eur J Cancer Clin Oncol 1998; 24: 1.799-1.804.
3. Colomer R, Ruibal A, Salvador L. Circulating tumor marker levels in advanced breast carcinoma correlate with the extent of metastatic disease. Cancer 1989; 64: 106-113.
4. Rubens J, Pamies MD, Crawford D. Tumor markers. An update. Medical Clinics of North America 1996; 80: 185-196.
5. Tondoni C, Hayes DF, Gelman R, Henderson IC, Kufe DW. Comparasion of CA 15.3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer. Cancer Res 1988; 48: 4.107-4.112.
6. Colomer R, Ruibal A, Genolla J, et al. Circulating CA 15.3 levels in the postsurgical follow-up of breast cancer patients and in non-malignant diseases. Breast Cancer Res Treat 1989; 13: 123-133.
7. Picó Navarro C, Herrero Doménech J, Meana García JA. Seguimiento del cáncer de mama. In: Dorta Delgado J, Germá Lluch JR, eds. Esquemas en el seguimiento del cáncer. Madrid: Arán Ediciones, SA, 1999; 125-131.
8. Hayes DF, Mesa-Tejada R, Papsidero LD, et al. Prediction of prognosis in primary breast cancer by detection of a high molecular weight mucin-like antigen using monoclonal antibodies DF3, F36 / 22 and CU18. J Clin Oncol 1991; 9: 1.113-1.123 .
9. Wojtacki J, Dziewulska-Bokiniec A, Kowalski DM, Zoltowska A, Ciesielski D, Suszko M. Pretreatment values of serum CA 15.3 antigen related to prognostic factors in breast cancer patients. Neoplasma 1996; 43 (4): 225-229.
10. Tampellini M, Berruti A, Gerbino A, et al. Relationship between CA 15.3 serum levels and disease extent in predicting overall survival of breast cancer patients with newly diagnosed metastatic disease. Br J Cancer 1997; 75 (5): 698-702.
11. Molina R, Jo J, Filella X, et al. C-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: prognostic value. Breast Cancer Res Treat 1998; 51: 109-119.
12. Hayes DF. Serum circulating tumor markers for breast cancer. Recent Results Cancer Res; 1996; 140: 101-113.
13. O'Hanlon DM, Kerin MJ, Kent P, Maher D, Grimes H, Given HF. An evaluation of preoperative CA 15.3 measurement in primary breast carcinoma. Br J Cancer 1995; 71: 1.288-1.291.
14. Shering SG, Sherry F, McDermott EW, O'Higgins Nj, Duffy MJ. Preoperative CA 15.3 concentrations predict outcome of patients with breast carcinoma. Cancer 1998 ; 83 (12): 2.521-2.527.
15. Ebeling FC, Schmitt UM, Untch M, et al. Tumour markers CEA and CA 15.3 as prognostic factors in breast cancer. Univariate and multivariate analysis. Anticancer Res 1999; 19: 2.545-2.550.
16. Altman DG, Lausen B, Sauerbrei W, Schumacher M. Da ngers of using «optimal» cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 1994; 86 (11): 829-841.
17. Saccani Jotti G, Bombardieri E. Circulating tumor markers in breast cancer. Anticancer Res 1990; 10: 253-258.
18. Wesseling J, Van Der Valk S, Hilkens J. A mechanism for inhibition of E-cadherin-mediated cell-cell adhesion by the membrane-associated mucin episialin/MUC1. Mol Biol Cell 1996; 7: 565-577.
19. Miles DW, Taylor- Papadimitriou J. Therapeutic aspects of polymorphic epithelial mucin in adenocarcinoma. Pharmacol Ther 1999; 82:97-106.
20. Koumarianou AA, Hudson M, Williams R, Epenetos AA, Stamp GWH. Development of a novel bi-specific monoclonal antibody approach for tumour targeting. Br J Cancer 1999; 81: 431-439.
21. Broadhead TJ, Gillespie AM, Coleman RE, et al. Phase 1 study of the cytotoxic immunoconjugate cmb-401 (hctm01 - calicheamicin) in patients with epithelial ovarian cancer: immune response and pharmacokinetics following repeated intravenous administration. Proc Am Soc Clin Oncol 1998; abstract 1693.
22. Scholl SM, Pouillart P. Vaccination against the tumoral mammary epithelial cells expressing MUC1 mucin. Bull Cancer 1997; 84: 61-64.